Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis

Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Results from 2 randomized, double‐blind, vehicle‐controlled phase 3 studies showed that twice‐daily crisaborole in children and adults with mild to moderate atopic derma...

Descripción completa

Detalles Bibliográficos
Autores principales: Purohit, Vivek, Riley, Steve, Tan, Huaming, Ports, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Non Covid Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540423/
https://www.ncbi.nlm.nih.gov/pubmed/32433779
http://dx.doi.org/10.1002/jcph.1624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540423/
https://www.ncbi.nlm.nih.gov/pubmed/32433779
http://dx.doi.org/10.1002/jcph.1624

Ejemplares similares